Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Bendamustine-bortezomib-dexamethasone in heavily pretreated immunotherapy-refractory myeloma

Claudio Cerchione • 10 Jun 2022
EHA 2022
Multiple Myeloma Bortezomib Dexamethasone

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, talks on the efficacy of the combination of bendamustine, bortezomib, and dexamethasone in heavily pretreated immunotherapy-refractory patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Claudio Cerchione

Integrated approaches to improve prognosis prediction in multiple myeloma
2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment
4:27
Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment
Claudio Cerchione • 18 Sep 2025
Performance of a novel prognostic index for multiple and smoldering myeloma
1:49
Performance of a novel prognostic index for multiple and smoldering myeloma
Claudio Cerchione • 18 Sep 2025
Looking forward to the upcoming MYELOMAS meeting in Rome, Italy
1:34
Looking forward to the upcoming MYELOMAS meeting in Rome, Italy
Claudio Cerchione • 18 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Claudio Cerchione • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Claudio Cerchione • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Claudio Cerchione • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Claudio Cerchione • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals